US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SPYRE THERAPEUTICS INC

17.29

-0.4200-2.37%

Post-market: 17.290.00000.00%17:50 EDT

Volume:326.26K

Turnover:5.65M

Market Cap:1.04B

PE:-5.75

High:17.73

Open:17.27

Low:17.00

Close:17.71

Loading ...

Overview Company News Filings

Spyre Therapeutics Q4 2024 GAAP EPS $(0.81) Beats $(1.01) Estimate

Spyre Therapeutics Inc Files for Mixed Shelf Offering of up to $500 Mln- SEC Filing

THOMSON REUTERS

Spyre Therapeutics Inc expected to post a loss of 99 cents a share - Earnings Preview

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation

Spyre Therapeutics initiated with early-stage designation at Goldman Sachs

Spyre Therapeutics (SYRE) Gets a Buy from Stifel Nicolaus

Spyre Therapeutics Announces Grants of Inducement Awards

Wall Street Set to Open Sharply Higher Wednesday on Positive Inflation Data

MT Newswires Live

Stifel Nicolaus Keeps Their Buy Rating on Spyre Therapeutics (SYRE)

Spyre Therapeutics Inc - Anticipates Cash Runway Into Second Half of 2028

THOMSON REUTERS

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Says it will be Added to Nasdaq Biotechnology Index

MT Newswires Live

BRIEF-Spyre Therapeutics Added To The Nasdaq Biotechnology Index

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

THOMSON REUTERS

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

TD says Spyre has ‘superior TL1A program’ after Teva data

JonesTrading Initiates Spyre Therapeutics at Hold

MT Newswires Live

Spyre Therapeutics initiated with a Hold at JonesResearch

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SYRE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","market":"US","secType":"STK","nameCN":"SPYRE THERAPEUTICS INC","latestPrice":17.29,"timestamp":1749844800000,"preClose":17.71,"halted":0,"volume":326257,"hourTrading":{"tag":"盘后","latestPrice":17.29,"preClose":17.29,"latestTime":"17:50 EDT","volume":9051,"amount":156480.99,"timestamp":1749851441764},"delay":0,"floatShares":46623089,"shares":60353561,"eps":-3.006383,"marketStatus":"Market Closed","change":-0.42,"latestTime":"06-13 16:00:00 EDT","open":17.27,"high":17.73,"low":16.995,"amount":5650089.689127,"amplitude":0.041502,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.006383,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750060800000},"marketStatusCode":7,"adr":0,"listingDate":1460001600000,"exchange":"NASDAQ","adjPreClose":17.71,"preHourTrading":{"tag":"盘前","latestPrice":17.64,"preClose":17.71,"latestTime":"09:28 EDT","volume":36,"amount":635.04,"timestamp":1749821280060},"postHourTrading":{"tag":"盘后","latestPrice":17.29,"preClose":17.29,"latestTime":"17:50 EDT","volume":9051,"amount":156480.99,"timestamp":1749851441764},"volumeRatio":0.6155667017874208,"impliedVol":0.7322,"impliedVolPercentile":0.456},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","floatShares":46623089,"roa":"-25.34%","roe":"-65.82%","lyrEps":-3.180151,"volumeRatio":0.6155667017874208,"shares":60353561,"dividePrice":0,"high":17.73,"amplitude":0.041502,"preClose":17.71,"low":16.995,"week52Low":10.91,"pbRate":"3.19","week52High":40.26,"institutionHeld":0,"latestPrice":17.29,"eps":-3.006383,"divideRate":0,"volume":326257,"delay":0,"ttmEps":-3.006383,"open":17.27,"prevYearClose":23.28,"prevWeekClose":16.97,"prevMonthClose":15.28,"prevQuarterClose":16.135,"fiveDayClose":16.97,"twentyDayClose":14.54,"sixtyDayClose":18.4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SYRE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514353050","title":"Spyre Therapeutics Q4 2024 GAAP EPS $(0.81) Beats $(1.01) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2514353050","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514353050?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:41","pubTimestamp":1740692469,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Q4 2024 GAAP EPS $(0.81) Beats $(1.01) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/02/44026855/spyre-therapeutics-q4-2024-gaap-eps-0-81-beats-1-01-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","LENZ"],"gpt_icon":0},{"id":"2514935824","title":"Spyre Therapeutics Inc Files for Mixed Shelf Offering of up to $500 Mln- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2514935824","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514935824?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:25","pubTimestamp":1740691554,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI15K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2514605528","title":"Spyre Therapeutics Inc  expected to post a loss of 99 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2514605528","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514605528?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:07","pubTimestamp":1740604027,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc  expected to post a loss of99cents a share - Earnings Preview Spyre Therapeutics Inc SYRE.OQ SYRE.O is expected to show a rise in quarterly revenue when it reports  results on F","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nL5N3PH2S1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"gpt_icon":0},{"id":"2512877102","title":"Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation","url":"https://stock-news.laohu8.com/highlight/detail?id=2512877102","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512877102?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:00","pubTimestamp":1739970000,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Feb. 19, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease  and other immune-mediated diseases, today announced a poster presentation at the 20th Congress of the European Crohn's and Colitis Organisation , held February 19-22, 2025, in Berlin, Germany, showing that combined inhibition of α4β7 integrin and TL1A cytokine is superior to either monotherapy in mouse models of colitis and coadministration demonstrates no drug-drug effects on exposure in non-human primates .Forward-Looking StatementsCertain statements in this press release, other than purely historical information, may constitute \"forward-looking statements\" within the meaning of the federal securities laws, including for purpos","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-poster-presentation-130000431.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-poster-presentation-130000431.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SYRE","LENZ","IBD"],"gpt_icon":0},{"id":"2512318132","title":"Spyre Therapeutics initiated with early-stage designation at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2512318132","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512318132?lang=en_us&edition=fundamental","pubTime":"2025-02-18 17:40","pubTimestamp":1739871605,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst Paul Choi initiated Spyre Therapeutics (SYRE) with an early-stage biotech designation. The firm sees an “attractive mix of cl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-initiated-with-early-stage-designation-at-goldman-sachs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-initiated-with-early-stage-designation-at-goldman-sachs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2237443382.USD","BK4127","LU2750360641.GBP","BK4552","IE00B19Z3B42.SGD","LU0061475181.USD","LU0096364046.USD","IE0004091025.USD","LU1868837136.USD","LU2237443465.HKD","LU2237443622.USD","LU2237443978.SGD","LU2471134523.USD","LU0106831901.USD","LU1791807156.HKD","IE0004086264.USD","LU2750360997.AUD","LU2471134952.CNY","LU1868837300.USD","LENZ","LU1868836757.USD","IE00B19Z3581.USD","LU2237438978.USD","LU2237443549.SGD","LU2471134796.USD","SYRE","LU2471134879.HKD","LU1868836591.USD","BK4516","BK4504","IE0034235188.USD","IE00BFXG1179.USD","LU2237443895.HKD","BK4533","LU1668664300.SGD","BK4585","BK4139","BK4550","IE0002270589.USD","LU1868836914.USD","BK4588","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2510851902","title":"Spyre Therapeutics (SYRE) Gets a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2510851902","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510851902?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:45","pubTimestamp":1739191554,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Spyre Therapeutics (SYRE – Research Report) today and set a price target of $7...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/spyre-therapeutics-syre-gets-a-buy-from-stifel-nicolaus-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/spyre-therapeutics-syre-gets-a-buy-from-stifel-nicolaus-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","SYRE","CFA","BK4139","SF"],"gpt_icon":0},{"id":"2509777836","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2509777836","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509777836?lang=en_us&edition=fundamental","pubTime":"2025-02-08 06:13","pubTimestamp":1738966380,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Feb. 7, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 35,000 shares of common stock of Spyre to three non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended . The stock options were approved on February 3, 2025 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635.Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease  and other immune-mediated disease products by combining bes","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-221300168.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-221300168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IBD","SYRE","LENZ","BK4139"],"gpt_icon":0},{"id":"2503644214","title":"Wall Street Set to Open Sharply Higher Wednesday on Positive Inflation Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2503644214","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503644214?lang=en_us&edition=fundamental","pubTime":"2025-01-15 22:20","pubTimestamp":1736950829,"startTime":"0","endTime":"0","summary":"US stocks look set to open sharply higher in Wednesday's trading session as investor sentiment was buoyed by encouraging inflation data released earlier in the morning.Dow Jones Industrial Average fut","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GIFT","PBHC","BK4211","BK4129","SYRE","LIF","SGBX","BK4077","FUND","BK4108","BK4023","MITQ","BK4190","BK4539","BK4120","OSTX","VMAR","LICY","BK4139"],"gpt_icon":1},{"id":"2503456956","title":"Stifel Nicolaus Keeps Their Buy Rating on Spyre Therapeutics (SYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503456956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503456956?lang=en_us&edition=fundamental","pubTime":"2025-01-14 09:10","pubTimestamp":1736817017,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Alex Thompson CFA from Stifel Nicolaus reiterated a Buy rating on Spyre Therapeutics (SYRE – Research Report). The ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-spyre-therapeutics-syre?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-spyre-therapeutics-syre?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYRE","SF"],"gpt_icon":0},{"id":"2503301460","title":"Spyre Therapeutics Inc - Anticipates Cash Runway Into Second Half of 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2503301460","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503301460?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:21","pubTimestamp":1736774510,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nFWN3O90QT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2503302193","title":"Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts","url":"https://stock-news.laohu8.com/highlight/detail?id=2503302193","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503302193?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:00","pubTimestamp":1736773200,"startTime":"0","endTime":"0","summary":"Phase 1 interim results expected for SPY002, two distinct extended half-life TL1A antibodies, in 2Q2025. Phase 1 interim results expected for SPY003, an extended half-life IL-23 antibody, in 2H2025. Phase 2 platform trial in ulcerative colitis  remains on track for initiation in mid-2025 with SPY001 , followed by SPY002 , SPY003 , and combinations thereof, with initial results expected in 2026. Strong balance sheet with preliminary cash, cash equivalents, and marketable securities balance of over $600M as of December 31, 2024*, anticipated to provide cash runway into the second half of 2028","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-highlights-2025-priorities-130000578.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-highlights-2025-priorities-130000578.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SYRE","IBD","RA","LENZ","BK4139"],"gpt_icon":0},{"id":"2500127227","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2500127227","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500127227?lang=en_us&edition=fundamental","pubTime":"2025-01-04 06:20","pubTimestamp":1735942800,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Jan. 3, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease , today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 21,000 shares of common stock of Spyre to one non-executive employee as an equity inducement award under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended . The stock options were approved on January 2, 2025 and were material to the employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635.Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease  products by combining best-in-class antibody engineering, rational therap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-222000096.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-222000096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SYRE","LENZ","IBD"],"gpt_icon":0},{"id":"2492389186","title":"Spyre Therapeutics Says it will be Added to Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492389186","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492389186?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:53","pubTimestamp":1734530001,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics  said Wednesday it will be added to the Nasdaq Biotechnology Index before trading begins Dec. 23.The company said the NBI tracks the performance of biotechnology and pharmaceutical companies listed on the Nasdaq stock exchange.Shares of the company were down 2% in recent Wednesday premarket activity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NDAQ","PSQ","NVIW.SI","QLD","BK4139","SQQQ","BK4588","IE00BGHQF748.EUR","TQQQ","LU2210149790.SGD","TSYW.SI","IE00B3QW5Z07.USD","BK4112","LENZ","USJW.SI","NQmain","MNQmain",".IXIC","IE00BKPKM429.USD","BK4585","USAW.SI","LU2095319765.USD","LU2210150020.SGD","IE00B64PRP62.GBP","SYRE","QID"],"gpt_icon":0},{"id":"2492185654","title":"BRIEF-Spyre Therapeutics Added To The Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492185654","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492185654?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:34","pubTimestamp":1734528878,"startTime":"0","endTime":"0","summary":"BRIEF-Spyre Therapeutics Added To The Nasdaq Biotechnology IndexDec 18 (Reuters) - Nasdaq Inc NDAQ.O:SPYRE THERAPEUTICS ADDED TO THE NASDAQ BIOTECHNOLOGY INDEXSource text: ID:nPn8Ss0lRaFurther company coverage: NDAQ.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA1D6D98:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SYRE","BK4585","IE00BKPKM429.USD","IE00B64PRP62.GBP","NDAQ","LU2210149790.SGD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210150020.SGD","LU2095319765.USD","BK4588","BK4139"],"gpt_icon":0},{"id":"2492164188","title":"Spyre Therapeutics Added to the Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492164188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492164188?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:00","pubTimestamp":1734526804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA1D6D98:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B3QW5Z07.USD","SYRE","BK4112","LU2210149790.SGD","NDAQ","IE00BGHQF748.EUR","BK4139","LU2210150020.SGD","BK4585","IE00BKPKM429.USD","BK4588","IE00B64PRP62.GBP","LU2095319765.USD"],"gpt_icon":0},{"id":"2492018392","title":"Spyre Therapeutics Added to the Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492018392","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492018392?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:00","pubTimestamp":1734526800,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Dec. 18, 2024 /PRNewswire/ --Spyre Therapeutics, Inc. , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease , today announced Spyre has been added to the Nasdaq Biotechnology Index , effective prior to market open, Monday, December 23, 2024.For more information about the Nasdaq Biotechnology Index, please visit this link.Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease  products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com.Follow Spyre Therapeutics on social media: @spyretx and LinkedIn","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OF7quuu2hXwKuKaISmsaxw--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/b47b05eb14d0fa90aed91f47beedafa6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OF7quuu2hXwKuKaISmsaxw--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/b47b05eb14d0fa90aed91f47beedafa6"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-added-nasdaq-biotechnology-130000760.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-added-nasdaq-biotechnology-130000760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ","PSQ","NVIW.SI","QLD","BK4139","SQQQ","BK4588","IE00BGHQF748.EUR","TQQQ","LU2210149790.SGD","TSYW.SI","IE00B3QW5Z07.USD","BK4112","LENZ","USJW.SI","NQmain","MNQmain",".IXIC","IE00BKPKM429.USD","BK4585","IBD","USAW.SI","LU2095319765.USD","LU2210150020.SGD","IE00B64PRP62.GBP","SYRE","QID"],"gpt_icon":1},{"id":"2492994931","title":"TD says Spyre has ‘superior TL1A program’ after Teva data","url":"https://stock-news.laohu8.com/highlight/detail?id=2492994931","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492994931?lang=en_us&edition=fundamental","pubTime":"2024-12-18 03:20","pubTimestamp":1734463218,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren recommends buying shares of Spyre Therapeutics (SYRE) following the “impressive results” from Teva (TEVA) and Sano...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/td-says-spyre-has-superior-tl1a-program-after-teva-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/td-says-spyre-has-superior-tl1a-program-after-teva-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4596","BK4559","BK4584","BK4139","BK4588","BK4566","BK4585","SYRE","TEVA","BK4557","TD","BK4207"],"gpt_icon":0},{"id":"2490385753","title":"JonesTrading Initiates Spyre Therapeutics at Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2490385753","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490385753?lang=en_us&edition=fundamental","pubTime":"2024-12-11 21:39","pubTimestamp":1733924348,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics, Inc (SYRE) has an average rating of buy and mean price target of $58.62, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SYRE","LENZ","BK4139"],"gpt_icon":0},{"id":"2490021958","title":"Spyre Therapeutics initiated with a Hold at JonesResearch","url":"https://stock-news.laohu8.com/highlight/detail?id=2490021958","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490021958?lang=en_us&edition=fundamental","pubTime":"2024-12-11 05:21","pubTimestamp":1733865692,"startTime":"0","endTime":"0","summary":"JonesResearch initiated coverage of Spyre Therapeutics (SYRE) with a Hold rating and no price target Spyre is a clinical-stage biotech developing h...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-initiated-with-a-hold-at-jonesresearch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-initiated-with-a-hold-at-jonesresearch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SYRE","LENZ"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":39,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-08","symbol":"SYRE","fiscalQuarterEnding":"2025/03","expectedEps":-0.76,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-0.74},{"market":"US","date":"2025-02-27","symbol":"SYRE","fiscalQuarterEnding":"2024/12","expectedEps":-1.1,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":-0.81},{"market":"US","date":"2024-11-07","symbol":"SYRE","fiscalQuarterEnding":"2024/09","expectedEps":-0.8,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-1.36},{"market":"US","date":"2024-08-07","symbol":"SYRE","fiscalQuarterEnding":"2024/06","expectedEps":-0.9,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"post","actualEps":-0.86},{"market":"US","date":"2024-05-09","symbol":"SYRE","fiscalQuarterEnding":"2024/03","expectedEps":-0.9,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"post","actualEps":-1.2}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.25,"hold":0.0833,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":12,"updateTime":1744171200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SYRE","date":"2025-06-13","current":-5.115786,"percent":0.430809,"low":-10.261647,"twenty":-7.156112,"median":-4.413455,"eighty":-3.545748,"high":-0.199399,"avg":-5.089499,"sd":1.948992,"marketCap":1068861565},"quantilePoints":[{"date":"2023-12-01","current":-1.902619,"twenty":-1.228042,"median":-0.216176,"eighty":-0.20611,"marketCap":560191990},{"date":"2023-12-08","current":-2.024974,"twenty":-2.048834,"median":-1.98164,"eighty":-0.890753,"marketCap":596217199},{"date":"2023-12-15","current":-1.815535,"twenty":-2.023412,"median":-1.966856,"eighty":-1.735642,"marketCap":534551743},{"date":"2023-12-22","current":-2.106706,"twenty":-2.023412,"median":-1.950531,"eighty":-1.82549,"marketCap":620281740},{"date":"2023-12-29","current":-2.507984,"twenty":-2.09023,"median":-1.996425,"eighty":-1.840422,"marketCap":738430643},{"date":"2024-01-05","current":-2.757559,"twenty":-2.278228,"median":-2.002935,"eighty":-1.873937,"marketCap":811913497},{"date":"2024-01-12","current":-2.567931,"twenty":-2.588728,"median":-2.024974,"eighty":-1.89995,"marketCap":756080936},{"date":"2024-01-19","current":-2.66458,"twenty":-2.653814,"median":-2.09023,"eighty":-1.902486,"marketCap":784537532},{"date":"2024-01-26","current":-3.303198,"twenty":-2.742878,"median":-2.292052,"eighty":-1.915254,"marketCap":972567189},{"date":"2024-02-02","current":-3.16373,"twenty":-3.116751,"median":-2.567931,"eighty":-1.947266,"marketCap":931503241},{"date":"2024-02-09","current":-2.89825,"twenty":-3.138772,"median":-2.61809,"eighty":-1.978684,"marketCap":853337655},{"date":"2024-02-16","current":-2.760005,"twenty":-3.112591,"median":-2.66458,"eighty":-1.997649,"marketCap":812633917},{"date":"2024-02-23","current":-2.496973,"twenty":-3.08641,"median":-2.66458,"eighty":-2.000865,"marketCap":735188752},{"date":"2024-03-01","current":-3.357028,"twenty":-3.117974,"median":-2.696389,"eighty":-2.009323,"marketCap":988416432},{"date":"2024-03-08","current":-4.14553,"twenty":-3.186241,"median":-2.748383,"eighty":-2.021849,"marketCap":1404464057},{"date":"2024-03-15","current":-4.473117,"twenty":-3.315921,"median":-2.757559,"eighty":-2.032927,"marketCap":1515447446},{"date":"2024-03-22","current":-4.253303,"twenty":-3.374155,"median":-2.84075,"eighty":-2.069838,"marketCap":1440976508},{"date":"2024-03-28","current":-3.948124,"twenty":-3.948124,"median":-2.884793,"eighty":-2.09023,"marketCap":1337584817},{"date":"2024-04-05","current":-3.822655,"twenty":-3.997689,"median":-2.933117,"eighty":-2.106706,"marketCap":1295077328},{"date":"2024-04-12","current":-4.169482,"twenty":-4.017483,"median":-2.950857,"eighty":-2.22293,"marketCap":1412578691},{"date":"2024-04-19","current":-3.844264,"twenty":-4.019298,"median":-3.071974,"eighty":-2.361175,"marketCap":1302398285},{"date":"2024-04-26","current":-3.508242,"twenty":-4.017483,"median":-3.149049,"eighty":-2.496973,"marketCap":1188557401},{"date":"2024-05-03","current":-4.312212,"twenty":-4.026871,"median":-3.180093,"eighty":-2.505537,"marketCap":1460934345},{"date":"2024-05-10","current":-4.183809,"twenty":-4.050631,"median":-3.290964,"eighty":-2.507984,"marketCap":1417432578},{"date":"2024-05-17","current":-4.180278,"twenty":-4.096445,"median":-3.334395,"eighty":-2.567931,"marketCap":1522561849},{"date":"2024-05-24","current":-3.614061,"twenty":-4.096445,"median":-3.364368,"eighty":-2.569154,"marketCap":1316331249},{"date":"2024-05-31","current":-4.872934,"twenty":-4.111605,"median":-3.38639,"eighty":-2.608303,"marketCap":1774844320},{"date":"2024-06-07","current":-4.694469,"twenty":-4.171641,"median":-3.527045,"eighty":-2.61809,"marketCap":1709842869},{"date":"2024-06-14","current":-4.393309,"twenty":-4.193693,"median":-3.59738,"eighty":-2.63375,"marketCap":1600152919},{"date":"2024-06-21","current":-3.360163,"twenty":-4.181695,"median":-3.573485,"eighty":-2.653814,"marketCap":1223855454},{"date":"2024-06-28","current":-3.277902,"twenty":-4.180281,"median":-3.545724,"eighty":-2.666048,"marketCap":1193893847},{"date":"2024-07-05","current":-3.553965,"twenty":-4.180278,"median":-3.545724,"eighty":-2.674367,"marketCap":1294442968},{"date":"2024-07-12","current":-4.13816,"twenty":-4.17596,"median":-3.564426,"eighty":-2.694186,"marketCap":1507221157},{"date":"2024-07-19","current":-4.113063,"twenty":-4.180278,"median":-3.593701,"eighty":-2.712782,"marketCap":1498080328},{"date":"2024-07-26","current":-4.387732,"twenty":-4.219183,"median":-3.614061,"eighty":-2.731867,"marketCap":1598121624},{"date":"2024-08-02","current":-3.651563,"twenty":-4.192391,"median":-3.674487,"eighty":-2.752053,"marketCap":1329990636},{"date":"2024-08-09","current":-6.773008,"twenty":-4.238871,"median":-3.689208,"eighty":-2.757559,"marketCap":1259650875},{"date":"2024-08-16","current":-7.111659,"twenty":-4.267009,"median":-3.707046,"eighty":-2.757559,"marketCap":1322633418},{"date":"2024-08-23","current":-6.972375,"twenty":-4.305721,"median":-3.744862,"eighty":-2.758537,"marketCap":1296729308},{"date":"2024-08-30","current":-7.851774,"twenty":-4.372067,"median":-3.796365,"eighty":-2.792303,"marketCap":1460280752},{"date":"2024-09-06","current":-7.655166,"twenty":-4.395693,"median":-3.839237,"eighty":-2.844176,"marketCap":1423715511},{"date":"2024-09-13","current":-8.038472,"twenty":-4.515004,"median":-3.909092,"eighty":-2.863261,"marketCap":1495003126},{"date":"2024-09-20","current":-8.260242,"twenty":-4.753435,"median":-3.923931,"eighty":-2.887484,"marketCap":1536248103},{"date":"2024-09-27","current":-7.800275,"twenty":-4.893011,"median":-3.931452,"eighty":-2.904612,"marketCap":1450702965},{"date":"2024-10-04","current":-7.980976,"twenty":-5.268067,"median":-3.990592,"eighty":-2.931282,"marketCap":1484309983},{"date":"2024-10-11","current":-7.857771,"twenty":-6.760445,"median":-4.004311,"eighty":-2.936176,"marketCap":1461396107},{"date":"2024-10-18","current":-8.969358,"twenty":-6.959266,"median":-4.01434,"eighty":-2.939112,"marketCap":1668130191},{"date":"2024-10-25","current":-9.530627,"twenty":-7.262959,"median":-4.019298,"eighty":-2.969942,"marketCap":1772515627},{"date":"2024-11-01","current":-9.303382,"twenty":-7.505129,"median":-4.04736,"eighty":-3.046528,"marketCap":1730252255},{"date":"2024-11-08","current":-9.47125,"twenty":-7.585076,"median":-4.070861,"eighty":-3.057293,"marketCap":2035390531},{"date":"2024-11-15","current":-6.988263,"twenty":-7.603794,"median":-4.087936,"eighty":-3.101825,"marketCap":1501791624},{"date":"2024-11-22","current":-7.566995,"twenty":-7.593388,"median":-4.106049,"eighty":-3.128495,"marketCap":1626162294},{"date":"2024-11-29","current":-7.766414,"twenty":-7.602508,"median":-4.133831,"eighty":-3.149049,"marketCap":1669017834},{"date":"2024-12-06","current":-7.397625,"twenty":-7.602508,"median":-4.146835,"eighty":-3.16373,"marketCap":1589764437},{"date":"2024-12-13","current":-6.589022,"twenty":-7.597044,"median":-4.169482,"eighty":-3.166361,"marketCap":1415994026},{"date":"2024-12-20","current":-6.517996,"twenty":-7.595055,"median":-4.180278,"eighty":-3.169847,"marketCap":1400730409},{"date":"2024-12-27","current":-6.466093,"twenty":-7.588386,"median":-4.182047,"eighty":-3.186241,"marketCap":1389576227},{"date":"2025-01-03","current":-6.651853,"twenty":-7.58308,"median":-4.215671,"eighty":-3.191991,"marketCap":1429496457},{"date":"2025-01-10","current":-6.135549,"twenty":-7.579794,"median":-4.247699,"eighty":-3.203592,"marketCap":1318541701},{"date":"2025-01-17","current":-5.632904,"twenty":-7.573901,"median":-4.253955,"eighty":-3.236074,"marketCap":1210522256},{"date":"2025-01-24","current":-5.900617,"twenty":-7.564263,"median":-4.27898,"eighty":-3.264517,"marketCap":1268054352},{"date":"2025-01-31","current":-6.280332,"twenty":-7.548513,"median":-4.304099,"eighty":-3.280514,"marketCap":1349655997},{"date":"2025-02-07","current":-6.187452,"twenty":-7.528128,"median":-4.345056,"eighty":-3.293411,"marketCap":1329695883},{"date":"2025-02-14","current":-6.26121,"twenty":-7.522652,"median":-4.382852,"eighty":-3.305947,"marketCap":1345546562},{"date":"2025-02-21","current":-5.815932,"twenty":-7.518271,"median":-4.394799,"eighty":-3.316941,"marketCap":1249855423},{"date":"2025-02-28","current":-5.708297,"twenty":-7.512359,"median":-4.473117,"eighty":-3.319102,"marketCap":1187428551},{"date":"2025-03-07","current":-5.647447,"twenty":-7.483663,"median":-4.605135,"eighty":-3.349687,"marketCap":1174770683},{"date":"2025-03-14","current":-5.227293,"twenty":-7.452562,"median":-4.749486,"eighty":-3.357028,"marketCap":1087371120},{"date":"2025-03-21","current":-5.264962,"twenty":-7.449529,"median":-4.833391,"eighty":-3.360163,"marketCap":1095206943},{"date":"2025-03-28","current":-5.198317,"twenty":-7.397625,"median":-4.89803,"eighty":-3.364368,"marketCap":1081343564},{"date":"2025-04-04","current":-3.706047,"twenty":-7.375771,"median":-4.833391,"eighty":-3.376602,"marketCap":770924425},{"date":"2025-04-11","current":-3.540883,"twenty":-7.371109,"median":-4.749486,"eighty":-3.378289,"marketCap":736567355},{"date":"2025-04-17","current":-3.671275,"twenty":-7.352984,"median":-4.694469,"eighty":-3.38477,"marketCap":763691357},{"date":"2025-04-25","current":-4.094327,"twenty":-7.328784,"median":-4.51381,"eighty":-3.412624,"marketCap":851693676},{"date":"2025-05-02","current":-4.378293,"twenty":-7.296115,"median":-4.473117,"eighty":-3.422161,"marketCap":910763726},{"date":"2025-05-09","current":-4.072986,"twenty":-7.269514,"median":-4.422481,"eighty":-3.450063,"marketCap":850985210},{"date":"2025-05-16","current":-4.384959,"twenty":-7.258044,"median":-4.393309,"eighty":-3.492778,"marketCap":916167055},{"date":"2025-05-23","current":-4.353184,"twenty":-7.252035,"median":-4.386346,"eighty":-3.506946,"marketCap":909528164},{"date":"2025-05-30","current":-4.491839,"twenty":-7.242247,"median":-4.381626,"eighty":-3.527827,"marketCap":938497873},{"date":"2025-06-06","current":-4.800924,"twenty":-7.228256,"median":-4.393309,"eighty":-3.543713,"marketCap":1003076183},{"date":"2025-06-13","current":-5.115786,"twenty":-7.156112,"median":-4.413455,"eighty":-3.545748,"marketCap":1068861565}],"updateTime":1749893032509}}}